NZ332713A - Substituted 1,3-benzodioxoles and use as antidiabetic, antihyperglycemic, and antiobesity agents - Google Patents
Substituted 1,3-benzodioxoles and use as antidiabetic, antihyperglycemic, and antiobesity agentsInfo
- Publication number
- NZ332713A NZ332713A NZ332713A NZ33271397A NZ332713A NZ 332713 A NZ332713 A NZ 332713A NZ 332713 A NZ332713 A NZ 332713A NZ 33271397 A NZ33271397 A NZ 33271397A NZ 332713 A NZ332713 A NZ 332713A
- Authority
- NZ
- New Zealand
- Prior art keywords
- hydrogen
- alkyl
- aryl
- independently
- benzodioxoles
- Prior art date
Links
- 239000003472 antidiabetic agent Substances 0.000 title abstract 3
- 230000003178 anti-diabetic effect Effects 0.000 title abstract 2
- 150000005529 1,3-benzodioxoles Chemical class 0.000 title 1
- 230000002058 anti-hyperglycaemic effect Effects 0.000 title 1
- 239000000883 anti-obesity agent Substances 0.000 title 1
- 229940125710 antiobesity agent Drugs 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 9
- 239000001257 hydrogen Substances 0.000 abstract 9
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 150000002431 hydrogen Chemical class 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 abstract 1
- 230000003579 anti-obesity Effects 0.000 abstract 1
- -1 arylakyl Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000005353 silylalkyl group Chemical group 0.000 abstract 1
- 125000004665 trialkylsilyl group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1896—Compounds having one or more Si-O-acyl linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
These compounds, which have anti-diabetic and/or antihyperglycemia and/or anti-obesity activity, have the formula (II), where: R1 and R6 are independently hydrogen, alkyl, trifluoromethyl, cyano, alkoxy, or halogen; R2 is hydrogen or trialkylsilyl; R3 is hydrogen or alkoxycarbonyl; or R2 and R3 are joined to form a ring (a): where R' is hydrogen, alkyl or aryl; R4 and R5 are independently hydrogen or alkyl; R7 and R8 are independently OR9 or NR10R11; R9 is hydrogen, alkyl, cycloalkyl, silylalkyl, aryl, arylakyl, alkoxyalkyl, heteroaryl, -CHR12COOR13, -CHR12C(O)R13, -CHR12CONR10R11, -CHR12OCOOR13, or -CHR12OC(O)R13, with the provision that R9 is not hydrogen in both R7 and R8; R10 and R11 are independently hydrogen, alkyl, aralkyl, aryl, furanylalkyl, or alkoxycarbonylalkyl; R12 and R13 are independently hydrogen, alkyl, aryl, or aralkyl; and their pharmaceutically acceptable salts thereof, the enantiomers thereof, the racemic mixtures thereof, and the diastereomeric mixtures thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64597096A | 1996-05-14 | 1996-05-14 | |
| PCT/US1997/008148 WO1997043273A1 (en) | 1996-05-14 | 1997-05-09 | Substituted 1, 3-benzodioxoles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ332713A true NZ332713A (en) | 2000-07-28 |
Family
ID=24591209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ332713A NZ332713A (en) | 1996-05-14 | 1997-05-09 | Substituted 1,3-benzodioxoles and use as antidiabetic, antihyperglycemic, and antiobesity agents |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0901484A1 (en) |
| JP (1) | JP2000510150A (en) |
| KR (1) | KR20000011001A (en) |
| AU (1) | AU730659B2 (en) |
| BR (1) | BR9708948A (en) |
| CA (1) | CA2254120A1 (en) |
| HU (1) | HUP9902088A2 (en) |
| IL (1) | IL126780A0 (en) |
| NZ (1) | NZ332713A (en) |
| WO (1) | WO1997043273A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019226491A1 (en) | 2018-05-21 | 2019-11-28 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| CN114423426B (en) * | 2019-07-24 | 2024-04-05 | 星座制药公司 | EZH2 inhibition combination therapy for the treatment of cancer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5061727A (en) * | 1990-05-04 | 1991-10-29 | American Cyanamid Company | Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles |
| US5482971A (en) * | 1993-10-01 | 1996-01-09 | American Cyanamid Company | Beta3 -adrenergic agents and their use in pharmaceutical compositions |
-
1997
- 1997-05-05 HU HU9902088A patent/HUP9902088A2/en unknown
- 1997-05-05 EP EP97924720A patent/EP0901484A1/en not_active Withdrawn
- 1997-05-09 KR KR1019980709151A patent/KR20000011001A/en not_active Application Discontinuation
- 1997-05-09 BR BR9708948A patent/BR9708948A/en unknown
- 1997-05-09 AU AU30067/97A patent/AU730659B2/en not_active Ceased
- 1997-05-09 JP JP09541097A patent/JP2000510150A/en active Pending
- 1997-05-09 WO PCT/US1997/008148 patent/WO1997043273A1/en not_active Application Discontinuation
- 1997-05-09 NZ NZ332713A patent/NZ332713A/en unknown
- 1997-05-09 IL IL12678097A patent/IL126780A0/en unknown
- 1997-05-09 CA CA002254120A patent/CA2254120A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2000510150A (en) | 2000-08-08 |
| WO1997043273A1 (en) | 1997-11-20 |
| AU730659B2 (en) | 2001-03-08 |
| IL126780A0 (en) | 1999-08-17 |
| CA2254120A1 (en) | 1997-11-20 |
| EP0901484A1 (en) | 1999-03-17 |
| KR20000011001A (en) | 2000-02-25 |
| BR9708948A (en) | 1999-08-03 |
| AU3006797A (en) | 1997-12-05 |
| HUP9902088A2 (en) | 2001-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS50297B (en) | Phenylphenanthridines with pde-iv inhibiting activity | |
| ES8703142A1 (en) | Benzimidazole derivatives | |
| PE20011348A1 (en) | IMIDAZOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL AGENTS | |
| ES8404990A1 (en) | Anti-hypertensive prolinol-based peptides. | |
| NZ503912A (en) | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds and their use as substance P antagonists | |
| NZ528997A (en) | Sulfonamides | |
| GB9408185D0 (en) | New benzamide derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | |
| FI935517A (en) | Phenoxy and phenoxyalkylpiperidines as antiviral agents | |
| AU637695B2 (en) | Therapeutic agents | |
| SE0101579D0 (en) | New compounds | |
| NZ332481A (en) | 5-[2,4-diaminopyrimidinylmethyl]phenyl substituted propanone (or propenone) isoquinoline derivatives and medicaments | |
| PE20050587A1 (en) | DIAZINDOL-DICARBONYL-PIPERAZINYL DERIVATIVES AS ANTIVIRAL AGENTS | |
| TW340109B (en) | Amide derivatives and their therapeutic use | |
| WO2004072088A3 (en) | Phosphine compound, intermediate, palladium-complex, and use thereof | |
| ATE72242T1 (en) | BENZOTHIAZEPINE DERIVATIVES. | |
| GR3003776T3 (en) | ||
| BG101601A (en) | Pharmaceutical piperazine compounds | |
| NZ332713A (en) | Substituted 1,3-benzodioxoles and use as antidiabetic, antihyperglycemic, and antiobesity agents | |
| BG106937A (en) | Novel indole derivatives | |
| MXPA03011032A (en) | Oxazol/ thiazol-derivatives activators of the hppar-alpha receptor. | |
| ATE229509T1 (en) | AZACYCLOOKTAN AND HEPTANE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | |
| DE3061188D1 (en) | 2-sulfonyl-quinoxalines, processes for their preparation and their use as microbicides | |
| CA2119002A1 (en) | Asymmetric Epoxidation Reaction | |
| NZ336235A (en) | Compounds containing 1,4-benzodioxane ring as antiobesity agents with antidiabetic, antihyperglycemic and antiobesity properties | |
| IL100430A (en) | Pharmaceutical compositions containing 2-phenyl- (ethyl or propyl)-2- (imidazol-1-yl) methyl-4- (phenylthio or phenoxy) methyl-1,3-dioxolane derivatives, certain such novel compounds and their preparation |